ES Therapeutics, PhytoTech Therapeutics, Ltd., UCB Biopharma, SK Life Science, UCB Biopharma
The Key Epilepsy Companies in the market include - Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Jazz Pharmaceuticals, SK Biopharmaceutical, Angelini Pharma/Ono Pharmaceutical, Novartis, Xenon Pharmaceuticals, Takeda, Ovid Therapeutics, Biohaven Pharmaceuticals/Knopp Biosciences, and others.
DelveInsight's 'Epilepsy Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Epilepsy, historical and forecasted epidemiology as well as the Epilepsy market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Epilepsy market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Epilepsy Market Forecast
Some of the key facts of the Epilepsy Market Report:
The Epilepsy market size was valued ~USD 9 billion in 2023 and is anticipated to grow with a significant CAGR of 7% during the study period (2020-2034)
In March 2025, QurAlis Corporation, a clinical-stage biotechnology company focused on developing precision medicines for neurodegenerative and neurological diseases, announced positive topline results from its Phase 1 proof-of-mechanism (PoM) clinical trial of QRL-101. The study, conducted in healthy volunteers, assessed biomarkers associated with amyotrophic lateral sclerosis (ALS) and epilepsy.
In November 2024, uniQure N.V. (NASDAQ: QURE), a pioneering gene therapy company focused on developing treatments for severe medical conditions, has announced that the first patient has been administered AMT-260 in the GenTLE Phase I/IIa clinical trial for refractory mesial temporal lobe epilepsy (MTLE).
In September 2024, Synergia Medical successfully implanted its neurostimulation technology in the first two patients participating in a study aimed at treating epilepsy. These procedures are part of a first-in-human trial being conducted at two locations in Belgium and one in Germany. The surgeries for the initial patients were performed earlier this month at the Belgian sites, according to the company.
In 2023, the Epilepsy Treatment Market in the US was valued at around USD 4.3 billion, representing approximately 48% of the total market revenue across the 7MM.
In 2023, the Epilepsy Treatment Market in the EU4 and the UK held a market share of approximately 29%. Among these countries, Germany had the largest market share, followed by France and the UK. These figures are expected to evolve during the forecast period.
In 2023, the Epilepsy Treatment Market Size in Japan was estimated to be around USD 2.1 billion.
In 2023, the total diagnosed prevalent cases of epilepsy in the 7MM were approximately 7 million, with an expected compound annual growth rate (CAGR) of 0.4% through 2034.
In 2023, the US had around 3.3 million total diagnosed epilepsy cases, with 14% of them in children and 86% in adults. The total number of epilepsy cases is anticipated to rise by 2034.
In 2023, the EU4 and the UK had approximately 1.3 million male cases and 1.5 million female cases of diagnosed epilepsy, with these figures expected to increase over the study period.
In 2023, Germany reported the highest number of epilepsy cases among the EU4 and the UK, with approximately 735 thousand cases. Of these, nearly 74% were focal seizures, 18% were generalized seizures, and 8% were classified as other determined or undetermined epileptic seizures.
In 2023, Japan had the second-highest number of diagnosed epilepsy cases among the 7MM, with approximately 890 thousand cases. These numbers are anticipated to change over the course of the study period.
In Japan, drug-resistant epilepsy/refractory cases accounted for the highest number of epilepsy cases, with approximately 82 thousand in 2023, followed by photosensitivity and childhood absence epilepsy, each with 44 thousand cases. These figures are projected to change by 2034.
The epilepsy market is expected to experience steady growth, with a compound annual growth rate (CAGR) of around 7% projected from 2024 to 2034. This growth across the 7MM will be fueled by the launch of new therapies, including LIBERVANT (diazepam buccal film), XEN1101, COMFYDE (carisbamate), Lorcaserin (E2023), and Soticlestat (TAK-935), among others.
DelveInsight estimates that in 2023, there were around 7 million total diagnosed prevalent cases of epilepsy across the 7MM. Of these, 48% of the cases were in the US, 39% were in the EU4 and the UK, and 13% were in Japan.
Key Epilepsy Companies: Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Jazz Pharmaceuticals, SK Biopharmaceutical, Angelini Pharma/Ono Pharmaceutical, Novartis, Xenon Pharmaceuticals, Takeda, Ovid Therapeutics, Biohaven Pharmaceuticals/Knopp Biosciences, and others
Key Epilepsy Therapies: LIBERVANT (diazepam buccal film), EPIDIOLEX/EPIDYOLEX (cannabidiol), XCOPRI/ONTOZRY (cenobamate), AFINITOR DISPERZ/VOTUBIA (everolimus), XEN1101/Azetukalner, Soticlestat (TAK-935), BHV-7000 (KB-3061), and others
The Epilepsy market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Epilepsy pipeline products will significantly revolutionize the Epilepsy market dynamics.
Epilepsy Overview
Epilepsy is a neurological disorder characterized by recurrent, unprovoked seizures caused by abnormal electrical activity in the brain. Seizures can vary in severity and may involve changes in behavior, consciousness, muscle control, or sensory perception. The condition can develop at any age and may result from various factors, including genetics, brain injury, infections, or structural brain abnormalities. Epilepsy is typically managed with medication, lifestyle adjustments, and sometimes surgery for more severe cases.
Get a Free sample for the Epilepsy Market Report
Epilepsy Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Epilepsy Epidemiology Segmentation:
The Epilepsy market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Download the report to understand which factors are driving Epilepsy epidemiology trends @ Epilepsy Epidemiology Forecast
Epilepsy Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Epilepsy market or expected to get launched during the study period. The analysis covers Epilepsy market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Epilepsy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Epilepsy Therapies and Key Companies
Epilepsy Market Strengths
Growing Focus On Providing Seizure-Free Life To Fuel Innovations.
Growth in The Demand For Epileptic Seizures Treatment
Epilepsy Market Opportunities
Growing funding for R&D of epilepsy is also contributing as a factor for the market growth.
Rising neurological diseases among population will also propel the growth of the market Increasing brain injuries cases due to road accidents will also drive the growth of this market
Scope of the Epilepsy Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Key Epilepsy Companies: Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Jazz Pharmaceuticals, SK Biopharmaceutical, Angelini Pharma/Ono Pharmaceutical, Novartis, Xenon Pharmaceuticals, Takeda, Ovid Therapeutics, Biohaven Pharmaceuticals/Knopp Biosciences, and others
Key Epilepsy Therapies: LIBERVANT (diazepam buccal film), EPIDIOLEX/EPIDYOLEX (cannabidiol), XCOPRI/ONTOZRY (cenobamate), AFINITOR DISPERZ/VOTUBIA (everolimus), XEN1101/Azetukalner, Soticlestat (TAK-935), BHV-7000 (KB-3061), and others
Epilepsy Therapeutic Assessment: Epilepsy current marketed and Epilepsy emerging therapies
Epilepsy Market Dynamics: Epilepsy market drivers and Epilepsy market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
Table of Contents
1. Epilepsy Market Report Introduction
2. Executive Summary for Epilepsy
3. SWOT analysis of Epilepsy
4. Epilepsy Patient Share (%) Overview at a Glance
5. Epilepsy Market Overview at a Glance
6. Epilepsy Disease Background and Overview
7. Epilepsy Epidemiology and Patient Population
8. Country-Specific Patient Population of Epilepsy
9. Epilepsy Current Treatment and Medical Practices
10. Epilepsy Unmet Needs
11. Epilepsy Emerging Therapies
12. Epilepsy Market Outlook
13. Country-Wise Epilepsy Market Analysis (2020–2034)
14. Epilepsy Market Access and Reimbursement of Therapies
15. Epilepsy Market Drivers
16. Epilepsy Market Barriers
17. Epilepsy Appendix
18. Epilepsy Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CTV News
a day ago
- CTV News
Simcoe County walks to raise money for ALS research
Residents of Simcoe County gathered at the Dorian Parker Centre at Sunnidale Park Saturday morning to raise awareness and money for ALS research. Amyotrophic lateral sclerosis (ALS) is a disease that progressively paralyzes people because the brain is no longer able to communicate with the muscles of the body. According to the ALS Canada Walk to End ALS website, Simcoe County raised more than $140,000 leading up to the walk. Each walk location had a fun zone station with stickers and craft materials and participants were welcomed to create their own signs for the walk. Proceeds from the walk go towards funding for Canadian ALS research. The walk is recognized in various provinces including Manitoba, Newfoundland & Labrador, Prince Edward Island, and Quebec.
CTV News
3 days ago
- CTV News
During ALS awareness month, Quebec man prepares cross-country wheelchair trek
Yannik Richard will travel across five provinces this fall to raise money and awareness for ALS. June is 'ALS Awareness Month,' and there is still no cure for the disease. A Quebec father who's been diagnosed with it is planning a cross-country journey in his motorized wheelchair to raise money and awareness. Yannik Richard of Prevost in the Laurentians is a family man whose life plans changed drastically 2 years ago. He says, 'I saw a neurologist, they transfered me to a neurologist... I was diagnosed with ALS.' Richard knows time is tight for ALS patients and wants to make the most of it. He's preparing to ride his motorized wheelchair across five provinces this fall. He says, 'I will ride 45 hundred km, starting from B.C. and coming to the end in Prevost.' A team of friends is already mapping the route and gathering sponsorships for the 35-day journey. Marie-Andrée Tremblay is the project manager for 'Team Yannik,' which they are calling La Grande Traversée. Tremblay says collecting resources has been going well. 'We have the RV from A.S. Levesque, we have the wheelchair, a motorized wheelchair. We have some money to pay the gas, and we are waiting for the airplane ticket now.' Claudine Cook, executive director of ALS Quebec, says this ride will help the 3,000 families in Canada touched by this disease. 'Because it's a fatal disease for every diagnosis, there's unfortunately someone who passes in a given year. So that's why you never see the numbers grow. So in Quebec, there's an estimated 600 people currently living with ALS with about 200 diagnosed and 200 people who pass every year.' Those ice-bucket challenges from years ago helped raise research money, yet Richard says he wants to help fund a better future for people with ALS by collecting donations along the ride. 'A message of hope for a generation to come. So we fight today for the orders for tomorrow. I want to teach my children that despite that, this life is beautiful and not unfair,' says Richard, who will be leaving B.C. on Sept. 22 and rolling east, expecting to arrive in Prevost in late October. Richard promises daily updates on his social media along the way.
Cision Canada
3 days ago
- Cision Canada
Aurora Expands Medical Cannabis Offerings in Australia with the Launch of IndiMed TEMPO 22
NASDAQ| TSX: ACB Canada's Largest Medical Cannabis Company Adds Two New Cultivars to Popular Brand Portfolio in the Australian Market EDMONTON, AB, June 5, 2025 /CNW/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, has expanded their popular IndiMed brand with the launch of IndiMed TEMPO 22, available through the company's subsidiary, MedReleaf Australia. With the same consistent quality and reliable supply, this new 22% THC potency creates a greater range of treatment options available to prescribers. "Expanding our portfolio in the value segment in Australia reinforces our commitment to meet increasingly diversified patient needs with accessible, high-quality medical cannabis options," said Andre Jerome, Executive Vice President of Global Business Development at Aurora. "As a global leader in medical cannabis, we're proud to offer a diverse range of products that reflect both local demand and our dedication to innovation worldwide." IndiMed remains one of the most prescribed medical cannabis brands for patients in Australia. The two new cultivars available include: IndiMed TEMPO 22 | Lemon Laser – Sativa, 22% THC, <1% CBD, Dried Cannabis (15g) IndiMed TEMPO 22 | Pickled Petrol – Indica, 22% THC, <1% CBD, Dried Cannabis (15g) Aurora's continued focus on international growth and deep commitment to providing patients with innovative products and expanded access enables the company to maintain its global leadership position. MedReleaf Australia, a wholly owned subsidiary of Aurora, is committed to quality and proudly meeting all TGA-GMP standards. For further information about the company's offerings, doctors and health care professionals can contact MedReleaf Australia's clinical support team or visit their website: About Aurora Cannabis Inc. Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and New Zealand. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co., as well as international brands, Pedanios, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched. Learn more at and follow us on X and LinkedIn. Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB". Contact For Investors: ICR, Inc. | [email protected] Forward Looking Information This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law (" forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding: the expansion of the Company's medical cannabis offerings in Australia and the availability of specific products; the Company's commitment to innovation, quality and expanded access; the Company's continued focus on international growth; and the Company's global leadership position. These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations (with respect to the Transaction and more generally with respect to future acquisitions), management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 20, 2024 (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at and filed with and available on the SEC's website at The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.
